Thus, a treatment targeting Alzheimer’s disease may need not only to reduce amyloid-β and tau but also may need to lower the burden of other degenerative pathologies that contributes to dementia, i.e. LATE-NC and LBs. Here, MAPT is linked to Alzheimer disease.